PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast - Reynold A. Panettieri, Jr., MD - Improving Outcomes in Uncontrolled Moderate-to-Severe Asthma: Choosing the Right Treatment for the Right Patient

Reynold A. Panettieri, Jr., MD - Improving Outcomes in Uncontrolled Moderate-to-Severe Asthma: Choosing the Right Treatment for the Right Patient

01/20/20 • 39 min

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

Go online to PeerView.com/EPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an asthma expert discusses advances in the understanding of the pathogenesis of asthma and novel targeted treatments that have been developed as a result. Strategies for identifying uncontrolled moderate-to-severe asthma patients who would benefit from these agents and clinical data for the currently available and emerging biologic therapies for asthma treatment are also discussed. Upon completion of this activity, participants should be better able to: Describe the economic impact and quality-of-life burden of moderate-to-severe asthma, Discuss the inflammatory mediators and mechanisms that provide the basis for the phenotypes and endotypes of severe asthma and their relevance to novel biologic therapies, Assess the latest clinical data with regard to efficacy and safety for currently available and emerging biologic therapies for the treatment of severe asthma, Apply treatment for patients with asthma based on symptom severity, disease phenotypes, exacerbation risk, and eligibility for biologic therapies

Previous Episode

undefined - Amit Singal, MD, MS - MasterClass & Tumor Board⁠—Joining Forces in Hepatocellular Carcinoma: Enhancing Multidisciplinary Care in an Era of New Therapeutic Solutions

Amit Singal, MD, MS - MasterClass & Tumor Board⁠—Joining Forces in Hepatocellular Carcinoma: Enhancing Multidisciplinary Care in an Era of New Therapeutic Solutions

Go online to PeerView.com/GWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView MasterClass and Tumor Board video activity, based on an educational session from The Liver Meeting® (American Association for the Study of Liver Diseases) in Boston, features a panel of hepatology, oncology, surgery, and interventional radiology experts, who provide their clinical perspectives on cutting-edge science that has validated, newly available systemic treatment options in HCC. Coupled with each MasterClass, the Tumor Board segments feature reflective case-centered discussions on the crucial role that hepatology clinicians serve across the HCC continuum of care. Upon completion of this activity, participants should be better able to: Evaluate the safety and efficacy data of multikinase and checkpoint inhibitors and antiangiogenic therapy indicated for advanced HCC, Summarize emerging clinical evidence on the use of novel systemic options in conjunction with or as an alternative to continued LRT for patients with intermediate HCC, Implement multidisciplinary team-based approaches to develop safe, personalized treatment algorithms that utilize novel components for patients with HCC

Next Episode

undefined - Joseph K. Han, MD - Driven by Type 2 Inflammation: The Potential of Novel Biologic Therapies in Managing Chronic Rhinosinusitis With Nasal Polyps

Joseph K. Han, MD - Driven by Type 2 Inflammation: The Potential of Novel Biologic Therapies in Managing Chronic Rhinosinusitis With Nasal Polyps

Go online to PeerView.com/QJM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic rhinosinusitis with nasal polyps (CRSwNP) discusses how to diagnose and differentiate this condition from other phenotypes of CRS. Novel agents for the treatment of CRSwNP are also explored, as well as how to incorporate these new therapies into treatment plans. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP) and its relevance to novel therapeutic targets, Apply evidence-based criteria to diagnose and differentiate CRSwNP from other phenotypes of CRS, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRSwNP, Develop individualized treatment plans, including the integration of emerging therapies if/when they become available, for the management of patients with CRSwNP